Kyle Faget Authors Article on Clinical Trial Agreement Considerations for Pharmaceutical Sponsors
13 January 2022
Foley & Lardner LLP Partner Kyle Faget authored an article, “Clinical Trial Agreement Considerations for Pharmaceutical Sponsors,” for LexisNexis Practical Guidance. The article provides guidance on key provisions when negotiating clinical trial agreements (CTAs) on behalf of pharmaceutical companies.
Faget, co-chair of Foley’s Health Care and Life Sciences Practice Groups, covers topics such as the role of contract research organizations (CROs) in CTA negotiations, preamble, confidentiality, intellectual property, indemnification, subject injury, limitation on liability, and publication rights.
Author(s)
Related Insights
14 February 2025
Foley Viewpoints
Wastin’ Away in Non-Complianceville
Everyone knows — or should know — that “The Terminator” is the best Halloween movie release and that “Die Hard” is the best Christmas movie (even though it was released in July).
06 March 2025
Events
SEC Enforcement Landscape: Lessons and Trends for Advisers
The SEC Enforcement program continues to aggressively pursue advisers on all fronts. This panel will discuss lessons from recent enforcement actions and insight into agency priorities that adviser legal and compliance personnel can incorporate into their firms’ compliance programs. Foley Partner Jim Lundy will moderate.
13 February 2025
Energy Current
Texas’ Power Transmission Infrastructure: Addressing Growing Demand from Data Centers and Crypto Mining
Texas is facing a rapidly evolving energy landscape, driven in part by the surging power demands of data centers and cryptocurrency mining operations.